XML 38 R27.htm IDEA: XBRL DOCUMENT v3.26.1
Convertible Preferred Stock and Stockholders’ Equity (Tables)
3 Months Ended
Mar. 31, 2026
Convertible Preferred Stock and Stockholders’ Equity [Abstract]  
Schedule of Outstanding Warrants

The following summarizes the Company’s outstanding warrants, excluding contingent warrants issuable upon exercise of the outstanding warrants as of March 31, 2026:

 

   Number of
Shares
   WA
Average
Exercise
Price
   WA
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2025   1,280,375   $24.85    2.73 
Granted            
Exercised   (144,087)        
Cancelled            
Outstanding as of March 31, 2026   1,136,288    26.26    2.49 
Warrants vested and exercisable as of March 31, 2026   1,136,288   $26.26    2.49 
Schedule of Stock Options

The following summarizes activity related to the Company’s stock options under the 2019 Plan and the 2022 Plan for the three months ended March 31, 2026:

 

           Weighted 
           Average 
       Weighted   Remaining 
       Average   Contractual 
   Number of   Exercise   Life 
   Shares   Price   (in years) 
Outstanding as of December 31, 2025   5   $28,504.73    6.8 
Granted            
Forfeited / cancelled   (3)   

8,109.00

     
Exercised            
Outstanding as of March 31, 2026   2    31,875.00    6.5 
Options vested and exercisable as of March 31, 2026   2   $31,875.00    6.5 
Schedule of Restricted Stock

The following summarizes activity related to the Company’s restricted stock awards granted under the 2022 Plan for the three months ended March 31, 2026:

 

       Weighted 
       Average 
   Number of   Grant Date 
   Shares   Fair Value 
Nonvested as of December 31, 2025   390   $71.55 
Granted        
Vested        
Forfeited   (127)   98.62 
Nonvested as of March 31, 2026   263   $57.92 
Schedule of Stock-Based Compensation Expense

Stock-based compensation expense related to stock options and restricted stock, for the three months ended March 31, 2026 and 2025 was as follows:

 

   For the Three Months Ended
March 31,
 
   2026   2025 
Selling, general and administrative  $22,305   $29,256 
Research and development        
Total  $22,305   $29,256